1. Zebrafish behavioral response to ivermectin: insights into potential neurological risk
- Author
-
Yigael Powrie, Morné Strydom, Marique Aucamp, Natalie Schellack, Vanessa Steenkamp, and Carine Smith
- Subjects
Neurological risk ,SARS-CoV-2 ,COVID-19 ,Veterinary formulation ,Viral ,Pharmacy and materia medica ,RS1-441 - Abstract
Ivermectin is a well-known and widely used anti-parasitic drug. Recently, in vitro data suggest anti-viral efficacy of the drug, albeit at much higher concentrations than currently approved. Despite warnings by several governing bodies, the (uncontrolled) human use of ivermectin has significantly increased during the COVID-19 epidemic. This study thus aimed to elucidate potential neurological risk of particularly the veterinary formulation of ivermectin in comparison to pure ivermectin. Zebrafish eggs (1hpf) and larvae (4dpf) were exposed to a range of concentrations of either pure ivermectin (IVM) or a veterinary formulation (V-IVM) for a period of 24 hours. Behavioral responses to both treatments were assessed at various timepoints using the pentylenetetrazol assay, the light–dark assay and a 5-day teratogenesis protocol. In addition, dissolution rates were calculated for both treatments. Acute responses of larvae at 4–
- Published
- 2022
- Full Text
- View/download PDF